

TABLE 170: RASH TREATMENT-EXPERIENCED WITH EMERGING TREATMENTS: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL (ALL GENOTYPES)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SIM12 + SOF12	PR48	0.66 (0.04 to 4.10)	-4.61 (-13.94 to 41.24)
SOF12 + LDV12		0.16 (0.04 to 0.53)	-11.32 (-14.49 to -5.97)
SOF12 + LDV12 + RBV12		0.64 (0.34 to 1.29)	-4.81 (-9.75 to 3.81)
SOF24 + LDV24 + RBV24		0.77 (0.34 to 1.84)	-3.11 (-9.34 to 10.98)
T12 PR48 q8		2.20 (1.37 to 3.65)	16.34 (5.09 to 34.62)
SIM12 PR24-48 RGT		1.02 (0.46 to 2.07)	0.28 (-7.47 to 14.23)
SIM12 PR48		1.44 (0.82 to 2.49)	6.01 (-2.46 to 19.21)
SOF12 + SIM12 + RBV12		1.79 (0.36 to 4.82)	10.68 (-8.90 to 49.52)
B32 PR36-48 RGT		2.21 (1.05 to 3.81)	16.54 (0.69 to 35.41)
SOF12 + RBV12		1.11 (0.38 to 2.63)	1.52 (-8.75 to 21.22)
SOF24 + RBV24		1.31 (0.28 to 3.67)	4.16 (-9.98 to 34.93)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
PAR/RIT12 + OMB12 + DAS12		0.05 (0.00 to 0.32)	-12.66 (-15.65 to -8.61)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.61 (0.23 to 1.69)	-5.22 (-10.88 to 9.08)
DCV24 + ASU24		0.28 (0.07 to 0.85)	-9.71 (-13.80 to -1.89)
DCV24 + ASU24 + PR24		2.62 (0.98 to 4.78)	22.13 (-0.21 to 48.49)
SOF12 + PR12		1.40 (0.66 to 2.74)	5.40 (-4.87 to 21.97)
GRZ12 + ELB12 (50 mg q.d.)		0.35 (0.06 to 1.38)	-8.81 (-13.68 to 4.94)
GRZ18 + ELB18 (50 mg q.d.)		0.05 (0.00 to 0.47)	-12.69 (-15.64 to -6.85)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.57 (0.13 to 1.89)	-5.87 (-12.43 to 11.55)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.53 (0.12 to 1.81)	-6.37 (-12.70 to 10.52)
SOF12 + LDV12	SIM12 + SOF12	0.23 (0.02 to 5.55)	-6.58 (-52.23 to 3.43)
SOF12 + LDV12 + RBV12		0.99 (0.14 to 17.81)	-0.09 (-46.17 to 12.51)
SOF24 + LDV24 + RBV24		1.20 (0.16 to 22.17)	1.58 (-44.13 to 18.12)
T12 PR48 q8		3.32 (0.51 to 57.99)	19.89 (-25.79 to 41.01)
SIM12 PR24-48 RGT		1.55 (0.21 to 28.88)	4.58 (-40.98 to 21.66)
SIM12 PR48		2.19 (0.33 to 37.00)	9.99 (-35.64 to 26.28)
SOF12 + SIM12 + RBV12		2.56 (0.58 to 26.19)	11.94 (-14.48 to 42.24)
B32 PR36-48 RGT		3.26 (0.55 to 48.40)	18.90 (-22.27 to 40.24)
SOF12 + RBV12		1.64 (0.23 to 27.17)	5.15 (-37.86 to 26.39)
SOF24 + RBV24		1.95 (0.22 to 32.13)	7.33 (-37.00 to 38.28)
PAR/RIT12 + OMB12 + DAS12		0.08 (0.00 to 2.10)	-7.97 (-53.81 to 1.11)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.92 (0.12 to 17.86)	-0.62 (-45.88 to 15.90)
DCV24 + ASU24		0.43 (0.05 to 7.40)	-4.80 (-50.52 to 5.80)
DCV24 + ASU24 + PR24		3.76 (0.67 to 56.26)	23.31 (-15.17 to 50.43)
SOF12 + PR12		2.08 (0.30 to 40.51)	8.86 (-36.39 to 29.20)
GRZ12 + ELB12 (50 mg q.d.)		0.54 (0.04 to 12.40)	-3.70 (-49.81 to 12.67)
GRZ18 + ELB18 (50 mg q.d.)		0.07 (0.00 to 2.34)	-7.80 (-53.48 to 1.98)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.89 (0.08 to 15.63)	-0.91 (-47.41 to 17.82)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.79 (0.08 to 17.98)	-1.76 (-47.23 to 17.50)
SOF12 + LDV12 + RBV12	SOF12 + LDV12	4.12 (1.23 to 15.66)	6.41 (1.18 to 14.11)
SOF24 + LDV24 + RBV24		4.82 (1.40 to 20.17)	8.13 (1.72 to 20.89)
T12 PR48 q8		13.89 (3.91 to 56.36)	27.60 (15.31 to 44.91)
SIM12 PR24-48 RGT		6.50 (1.47 to 28.86)	11.59 (2.23 to 25.28)
SIM12 PR48		9.15 (2.44 to 36.84)	17.32 (7.58 to 29.72)
SOF12 + SIM12 + RBV12		10.92 (1.50 to 58.61)	21.76 (1.85 to 60.48)
B32 PR36-48 RGT		13.80 (3.50 to 59.83)	27.74 (11.46 to 46.16)
SOF12 + RBV12		6.87 (1.49 to 34.62)	12.63 (2.02 to 31.96)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV24		8.13 (1.19 to 42.35)	15.35 (0.66 to 45.75)
PAR/RIT12 + OMB12 + DAS12		0.34 (0.02 to 3.09)	-1.27 (-6.24 to 2.20)
PAR/RIT12 + OMB12 + DAS12 + RBV12		3.93 (0.82 to 18.49)	6.07 (-0.88 to 19.58)
DCV24 + ASU24		1.76 (0.29 to 9.62)	1.52 (-3.83 to 8.96)
DCV24 + ASU24 + PR24		16.15 (3.58 to 72.49)	33.38 (10.41 to 59.21)
SOF12 + PR12		8.80 (2.02 to 38.23)	16.62 (5.37 to 32.59)
GRZ12 + ELB12 (50 mg q.d.)		2.18 (0.25 to 13.92)	2.41 (-3.79 to 16.05)
GRZ18 + ELB18 (50 mg q.d.)		0.28 (0.01 to 4.06)	-1.33 (-6.21 to 4.22)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		3.46 (0.54 to 20.94)	5.32 (-2.12 to 22.62)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		3.28 (0.48 to 21.28)	4.81 (-2.35 to 21.53)
SOF24 + LDV24 + RBV24	SOF12 + LDV12 + RBV12	1.20 (0.48 to 2.79)	1.68 (-6.57 to 13.63)
T12 PR48 q8		3.39 (1.59 to 7.08)	21.03 (8.05 to 38.02)
SIM12 PR24-48 RGT		1.59 (0.53 to 4.03)	5.06 (-6.54 to 19.01)
SIM12 PR48		2.24 (0.98 to 4.74)	10.75 (-0.33 to 23.20)
SOF12 + SIM12 + RBV12		2.74 (0.47 to 8.80)	15.20 (-6.33 to 54.30)
B32 PR36-48 RGT		3.42 (1.23 to 7.76)	21.14 (3.05 to 40.44)
SOF12 + RBV12		1.73 (0.49 to 4.91)	6.18 (-6.62 to 25.87)
SOF24 + RBV24		2.02 (0.37 to 6.85)	8.83 (-8.14 to 39.64)
PAR/RIT12 + OMB12 + DAS12		0.08 (0.01 to 0.52)	-7.77 (-15.91 to -2.91)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.96 (0.30 to 2.85)	-0.30 (-9.55 to 13.19)
DCV24 + ASU24		0.43 (0.09 to 1.52)	-4.77 (-13.70 to 3.24)
DCV24 + ASU24 + PR24		4.02 (1.19 to 9.51)	26.71 (2.31 to 53.16)
SOF12 + PR12		2.16 (0.78 to 5.34)	10.05 (-3.16 to 26.53)
GRZ12 + ELB12 (50 mg q.d.)		0.52 (0.08 to 2.43)	-4.00 (-13.20 to 9.89)
GRZ18 + ELB18 (50 mg q.d.)		0.07 (0.00 to 0.79)	-7.81 (-16.01 to -1.42)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.87 (0.17 to 3.48)	-1.11 (-11.47 to 16.66)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.81 (0.16 to 3.25)	-1.58 (-11.74 to 15.60)
T12 PR48 q8	SOF24 + LDV24 + RBV24	2.84 (1.14 to 7.33)	19.13 (2.90 to 37.02)
SIM12 PR24-48 RGT		1.33 (0.40 to 3.73)	3.38 (-12.46 to 17.52)
SIM12 PR48		1.87 (0.70 to 4.88)	8.96 (-6.32 to 22.71)
SOF12 + SIM12 + RBV12		2.25 (0.38 to 8.32)	13.13 (-10.70 to 52.85)
B32 PR36-48 RGT		2.84 (0.91 to 7.41)	19.25 (-1.75 to 38.81)
SOF12 + RBV12		1.44 (0.37 to 4.62)	4.45 (-12.20 to 24.41)
SOF24 + RBV24		1.67 (0.29 to 6.19)	6.98 (-12.76 to 38.07)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
PAR/RIT12 + OMB12 + DAS12		0.07 (0.00 to 0.50)	-9.54 (-23.01 to -2.80)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.80 (0.23 to 2.73)	-2.06 (-16.02 to 11.93)
DCV24 + ASU24		0.36 (0.07 to 1.42)	-6.44 (-20.53 to 2.62)
DCV24 + ASU24 + PR24		3.35 (0.90 to 9.17)	24.89 (-1.74 to 51.47)
SOF12 + PR12		1.80 (0.57 to 5.23)	8.25 (-9.06 to 25.50)
GRZ12 + ELB12 (50 mg q.d.)		0.45 (0.06 to 2.23)	-5.49 (-19.54 to 8.79)
GRZ18 + ELB18 (50 mg q.d.)		0.06 (0.00 to 0.71)	-9.44 (-23.15 to -1.95)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.74 (0.13 to 3.13)	-2.60 (-17.64 to 15.40)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.68 (0.13 to 2.93)	-3.20 (-17.83 to 14.04)
SIM12 PR24-48 RGT	T12 PR48 q8	0.47 (0.17 to 1.06)	-15.79 (-35.68 to 1.33)
SIM12 PR48		0.66 (0.38 to 1.04)	-10.03 (-25.19 to 1.06)
SOF12 + SIM12 + RBV12		0.81 (0.15 to 2.33)	-5.81 (-32.74 to 33.55)
B32 PR36-48 RGT		1.01 (0.42 to 1.92)	0.23 (-23.56 to 21.28)
SOF12 + RBV12		0.51 (0.16 to 1.27)	-14.49 (-34.55 to 6.46)
SOF24 + RBV24		0.59 (0.12 to 1.75)	-11.88 (-35.43 to 19.16)
PAR/RIT12 + OMB12 + DAS12		0.02 (0.00 to 0.13)	-28.96 (-45.90 to -17.76)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.28 (0.12 to 0.61)	-21.08 (-33.96 to -10.55)
DCV24 + ASU24		0.13 (0.03 to 0.39)	-25.68 (-43.39 to -13.33)
DCV24 + ASU24 + PR24		1.19 (0.40 to 2.40)	5.74 (-23.60 to 33.14)
SOF12 + PR12		0.63 (0.26 to 1.42)	-10.86 (-32.03 to 9.25)
GRZ12 + ELB12 (50 mg q.d.)		0.16 (0.02 to 0.67)	-24.75 (-42.98 to -8.06)
GRZ18 + ELB18 (50 mg q.d.)		0.02 (0.00 to 0.22)	-28.85 (-46.54 to -16.55)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.26 (0.06 to 0.90)	-21.60 (-40.84 to -2.44)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.24 (0.05 to 0.85)	-22.20 (-41.19 to -3.86)
SIM12 PR48	SIM12 PR24-48 RGT	1.42 (0.58 to 3.81)	5.65 (-10.27 to 20.98)
SOF12 + SIM12 + RBV12		1.72 (0.31 to 6.22)	9.87 (-14.03 to 50.13)
B32 PR36-48 RGT		2.16 (0.77 to 5.55)	15.94 (-5.39 to 36.74)
SOF12 + RBV12		1.09 (0.30 to 3.52)	1.18 (-15.89 to 21.91)
SOF24 + RBV24		1.28 (0.23 to 4.78)	3.69 (-16.62 to 35.70)
PAR/RIT12 + OMB12 + DAS12		0.05 (0.00 to 0.39)	-12.97 (-26.68 to -4.28)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.60 (0.19 to 2.32)	-5.41 (-19.74 to 10.74)
DCV24 + ASU24		0.28 (0.06 to 1.09)	-9.77 (-24.16 to 0.61)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
DCV24 + ASU24 + PR24		2.55 (0.76 to 6.72)	21.51 (-4.87 to 48.94)
SOF12 + PR12		1.36 (0.50 to 3.87)	4.93 (-11.97 to 23.09)
GRZ12 + ELB12 (50 mg q.d.)		0.34 (0.05 to 1.71)	-8.76 (-23.15 to 6.58)
GRZ18 + ELB18 (50 mg q.d.)		0.04 (0.00 to 0.54)	-12.86 (-26.66 to -3.57)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.55 (0.11 to 2.38)	-6.00 (-21.08 to 12.74)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.52 (0.10 to 2.25)	-6.41 (-21.21 to 11.42)
SOF12 + SIM12 + RBV12	SIM12 PR48	1.22 (0.24 to 3.59)	4.37 (-18.73 to 43.22)
B32 PR36-48 RGT		1.53 (0.68 to 3.01)	10.32 (-8.32 to 29.81)
SOF12 + RBV12		0.78 (0.26 to 1.87)	-4.31 (-18.80 to 14.58)
SOF24 + RBV24		0.90 (0.19 to 2.76)	-1.88 (-20.67 to 28.70)
PAR/RIT12 + OMB12 + DAS12		0.04 (0.00 to 0.22)	-18.64 (-31.10 to -9.81)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.42 (0.17 to 1.15)	-11.01 (-22.56 to 2.55)
DCV24 + ASU24		0.19 (0.05 to 0.58)	-15.36 (-27.86 to -6.07)
DCV24 + ASU24 + PR24		1.80 (0.64 to 3.78)	15.72 (-8.54 to 42.25)
SOF12 + PR12		0.97 (0.38 to 2.39)	-0.58 (-17.65 to 18.72)
GRZ12 + ELB12 (50 mg q.d.)		0.24 (0.04 to 1.06)	-14.50 (-28.22 to 0.88)
GRZ18 + ELB18 (50 mg q.d.)		0.03 (0.00 to 0.36)	-18.62 (-31.22 to -8.75)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.40 (0.08 to 1.45)	-11.57 (-25.88 to 7.05)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.37 (0.08 to 1.40)	-12.10 (-26.24 to 6.15)
B32 PR36-48 RGT	SOF12+ SIM12 + RBV12	1.23 (0.46 to 5.03)	5.50 (-29.26 to 27.54)
SOF12 + RBV12		0.63 (0.17 to 3.10)	-8.52 (-45.82 to 15.80)
SOF24 + RBV24		0.74 (0.14 to 3.88)	-5.48 (-43.91 to 25.71)
PAR/RIT12 + OMB12 + DAS12		0.03 (0.00 to 0.34)	-23.24 (-61.82 to -3.42)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.35 (0.09 to 2.31)	-15.24 (-53.88 to 8.44)
DCV24 + ASU24		0.16 (0.04 to 0.86)	-19.92 (-57.95 to -0.83)
DCV24 + ASU24 + PR24		1.45 (0.59 to 5.08)	10.10 (-20.35 to 34.03)
SOF12 + PR12		0.79 (0.23 to 4.42)	-5.02 (-45.05 to 21.61)
GRZ12 + ELB12 (50 mg q.d.)		0.20 (0.03 to 1.64)	-18.76 (-57.69 to 4.36)
GRZ18 + ELB18 (50 mg q.d.)		0.03 (0.00 to 0.46)	-23.15 (-61.53 to -3.26)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.32 (0.06 to 2.18)	-15.78 (-54.27 to 8.91)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.31 (0.05 to 2.27)	-16.04 (-55.32 to 9.03)
SOF12 + RBV12	B32 PR36-48 RGT	0.51 (0.22 to 1.10)	-14.23 (-29.97 to 2.38)
SOF24 + RBV24		0.60 (0.16 to 1.43)	-11.32 (-29.84 to 11.90)
PAR/RIT12 + OMB12 + DAS12		0.02 (0.00 to 0.17)	-29.16 (-47.68 to -12.92)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.28 (0.10 to 0.97)	-21.37 (-40.47 to -0.50)
DCV24 + ASU24		0.13 (0.04 to 0.34)	-25.85 (-42.58 to -11.69)
DCV24 + ASU24 + PR24		1.17 (0.62 to 1.98)	5.16 (-11.27 to 24.44)
SOF12 + PR12		0.63 (0.25 to 1.74)	-10.93 (-33.46 to 12.80)
GRZ12 + ELB12 (50 mg q.d.)		0.16 (0.02 to 0.77)	-24.80 (-44.33 to -4.33)
GRZ18 + ELB18 (50 mg q.d.)		0.02 (0.00 to 0.24)	-29.00 (-47.66 to -12.50)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.26 (0.06 to 1.06)	-21.83 (-41.84 to 1.22)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.25 (0.05 to 1.00)	-22.02 (-42.74 to 0.01)
SOF24 + RBV24	SOF12 + RBV12	1.18 (0.26 to 3.96)	2.59 (-18.50 to 30.32)
PAR/RIT12 + OMB12 + DAS12		0.05 (0.00 to 0.39)	-14.11 (-33.41 to -3.73)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.55 (0.16 to 2.29)	-6.48 (-25.96 to 9.69)
DCV24 + ASU24		0.26 (0.06 to 0.88)	-10.90 (-29.44 to -0.98)
DCV24 + ASU24 + PR24		2.31 (0.84 to 6.15)	19.68 (-3.59 to 43.53)
SOF12 + PR12		1.26 (0.39 to 4.48)	3.83 (-19.06 to 23.59)
GRZ12 + ELB12 (50 mg q.d.)		0.31 (0.04 to 1.77)	-9.84 (-29.91 to 6.32)
GRZ18 + ELB18 (50 mg q.d.)		0.04 (0.00 to 0.56)	-14.06 (-33.36 to -2.94)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.51 (0.10 to 2.45)	-7.06 (-27.27 to 11.86)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.49 (0.09 to 2.45)	-7.40 (-27.86 to 11.41)
PAR/RIT12 + OMB12 + DAS12	SOF24 + RBV24	0.04 (0.00 to 0.49)	-16.76 (-47.24 to -2.20)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.47 (0.12 to 3.02)	-8.93 (-39.83 to 11.03)
DCV24 + ASU24		0.22 (0.05 to 1.08)	-13.39 (-42.99 to 0.38)
DCV24 + ASU24 + PR24		1.95 (0.68 to 7.93)	16.41 (-11.36 to 43.13)
SOF12 + PR12		1.05 (0.31 to 5.87)	0.94 (-30.36 to 24.10)
GRZ12 + ELB12 (50 mg q.d.)		0.28 (0.03 to 2.10)	-12.24 (-43.81 to 6.79)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ18 + ELB18 (50 mg q.d.)		0.04 (0.00 to 0.60)	-16.63 (-47.43 to -1.90)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.43 (0.08 to 3.00)	-9.57 (-40.19 to 11.95)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.42 (0.07 to 3.02)	-9.71 (-41.83 to 11.65)
PAR/RIT12 + OMB12 + DAS12 + RBV12	PAR/RIT12 + OMB12 + DAS12	11.90 (1.80 to 164.20)	7.39 (1.74 to 20.79)
DCV24 + ASU24		5.32 (0.55 to 88.90)	2.84 (-1.34 to 10.24)
DCV24 + ASU24 + PR24		48.60 (6.27 to 703.90)	34.71 (11.88 to 60.75)
SOF12 + PR12		26.64 (3.56 to 399.40)	18.00 (7.47 to 34.05)
GRZ12 + ELB12 (50 mg q.d.)		6.48 (0.55 to 124.00)	3.76 (-1.25 to 17.41)
GRZ18 + ELB18 (50 mg q.d.)		0.91 (0.02 to 27.75)	-0.04 (-3.58 to 5.55)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		10.73 (1.01 to 174.50)	6.78 (0.02 to 24.06)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		10.02 (0.95 to 178.50)	6.22 (-0.14 to 22.77)
DCV24 + ASU24	PAR/RIT12 + OMB12 + DAS12 + RBV12	0.46 (0.09 to 1.85)	-4.29 (-18.54 to 4.04)
DCV24 + ASU24 + PR24		4.22 (1.03 to 12.61)	26.84 (0.41 to 52.98)
SOF12 + PR12		2.26 (0.66 to 7.32)	10.28 (-6.53 to 27.38)
GRZ12 + ELB12 (50 mg q.d.)		0.55 (0.07 to 3.12)	-3.52 (-17.68 to 10.95)
GRZ18 + ELB18 (50 mg q.d.)		0.07 (0.00 to 0.96)	-7.33 (-21.07 to -0.20)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.92 (0.16 to 4.27)	-0.60 (-15.77 to 16.62)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.86 (0.15 to 4.16)	-1.17 (-15.72 to 15.67)
DCV24 + ASU24 + PR24	DCV24 + ASU24	8.90 (2.86 to 31.87)	31.37 (10.07 to 56.07)
SOF12 + PR12		4.91 (1.30 to 23.33)	14.83 (2.58 to 31.76)
GRZ12 + ELB12 (50 mg q.d.)		1.21 (0.14 to 9.21)	0.74 (-7.71 to 14.77)
GRZ18 + ELB18 (50 mg q.d.)		0.16 (0.00 to 2.51)	-2.82 (-10.43 to 2.99)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		2.01 (0.35 to 12.40)	3.62 (-5.42 to 20.90)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.91 (0.29 to 11.84)	3.24 (-5.96 to 20.14)
SOF12 + PR12	DCV24 + ASU24 + PR24	0.54 (0.21 to 1.77)	-16.32 (-45.51 to 12.05)
GRZ12 + ELB12 (50 mg q.d.)		0.13 (0.02 to 0.71)	-30.26 (-57.02 to -4.67)
GRZ18 + ELB18 (50 mg q.d.)		0.02 (0.00 to 0.22)	-34.62 (-60.61 to -11.64)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.22 (0.05 to 1.01)	-27.08 (-53.99 to 0.09)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.21 (0.04 to 0.95)	-27.55 (-55.08 to -0.83)
GRZ12 + ELB12 (50 mg q.d.)	SOF12 + PR12	0.25 (0.04 to 1.24)	-13.65 (-30.80 to 3.15)
GRZ18 + ELB18 (50 mg q.d.)		0.03 (0.00 to 0.39)	-17.89 (-34.02 to -6.94)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		0.41 (0.08 to 1.64)	-10.79 (-28.66 to 8.29)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		0.38 (0.08 to 1.61)	-11.30 (-29.13 to 7.96)
GRZ18 + ELB18 (50 mg q.d.)	GRZ12 + ELB12 (50 mg q.d.)	0.13 (0.00 to 2.00)	-3.72 (-16.80 to 1.98)
GRZ12 + ELB12 (50 mg q.d.) + RBV12		1.61 (0.27 to 12.48)	2.56 (-9.65 to 19.02)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		1.51 (0.25 to 10.99)	2.19 (-10.37 to 18.15)
GRZ12 + ELB12 (50 mg q.d.) + RBV12	GRZ18 + ELB18 (50 mg q.d.)	12.04 (0.93 to 382.50)	6.58 (-0.31 to 23.88)
GRZ18 + ELB18 (50 mg q.d.) + RBV18		11.19 (0.80 to 396.20)	6.14 (-0.85 to 22.29)
GRZ18 + ELB18 (50 mg q.d.) + RBV18	GRZ12 + ELB12 (50 mg q.d.) + RBV12	0.94 (0.17 to 5.08)	-0.43 (-16.03 to 15.16)
Random effect model	Residual deviance	54.11 vs. 51 data points	
	Deviance information criteria	299.747	
Fixed effect model	Residual deviance	56.99 vs. 51 data points	
	Deviance information criteria	300.661	

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; Crl = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; q.d. = once daily; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir; vs. = versus.
Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.